HMGB1 related pathways in epilepsy

Basit Öğe Kaydı
dc.authorscopusid57219390008
dc.authorscopusid57194432176
dc.authorscopusid57204184451
dc.authorscopusid58016862300
dc.contributor.authorSoyturk, Hayriye
dc.contributor.authorKilic, Umit
dc.contributor.authorOnal, Cansu
dc.contributor.authorYildiz, Aysegül
dc.date.accessioned2024-09-25T19:45:28Z
dc.date.available2024-09-25T19:45:28Z
dc.date.issued2022
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractEpilepsy is one of the most common neurological illnesses, affecting an estimated 70 million individuals worldwide. A mechanistic approach to discovering crucial pathogenic brain abnormalities driving seizure onset, recurrence, and advancement is critical for generating novel and rational treatment methods that may modify or prevent disease progression. In this context, an increasing body of evidence suggests that neuroinflammation plays a role in drug-resistant epilepsies. The high mobility group box 1 (HMGB1) protein, a key regulator of neuroinflammation, has been associated with several neurological disorders, including epilepsy. Increased levels of HMGB1, one of the most prominent pro-inflammatory cytokines, have been linked to seizure length, recurrence, and epilepsy development. Therefore, HMGB1 has attracted a lot of attention and has been developed quickly. According to clinical and experimental data, HMGB1 isoforms may serve as neurobiological biomarkers for epileptogenesis and drug-resistant epilepsy. These novel findings suggest that the HMGB1 system could be targeted to prevent seizure generation and provide therapeutically relevant prognostic markers that can also predict a patient's response to therapy. This section will recap epileptogenesis theory and examine the relationships between epilepsy and neuroinflammatory pathways using experimental and clinical evidence. © 2023 by Nova Science Publishers, Inc. All rights reserved.en_US
dc.identifier.endpage264en_US
dc.identifier.isbn979-888697466-9
dc.identifier.isbn979-888697408-9
dc.identifier.scopus2-s2.0-85143992849en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage239en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13039
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherNova Science Publishers, Inc.en_US
dc.relation.ispartofHMGB1: Functions, Inhibitors and Clinical Significanceen_US
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectEpilepsyen_US
dc.subjectHMGB1en_US
dc.subjectNeuroinflammationen_US
dc.titleHMGB1 related pathways in epilepsyen_US
dc.typeBook Chapteren_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu